Omnicell

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Omnicell reports robust Q4 earnings, eyes Advanced Services growth

Omnicell's Q4 2022 earnings call highlighted a strong financial performance, cost-saving initiatives, and strategic priorities for 2023. The company aims to drive growth through Advanced Services expansion, while navigating challenges such as market conditions and regulatory impacts. By focusing on operational efficiency and prudent financial management, Omnicell positions itself for sustainable growth and profitability.

Omnicell surpasses Q1 revenue targets, eyes automation for growth

Omnicell's Q1 2023 earnings call showcased robust financial performance, strategic partnerships, and cost containment efforts. The company is well-positioned to capitalize on the growing demand for automation in healthcare.

Omnicell surpasses Q2 expectations, focuses on AI strategy growth

Omnicell's Q2 performance exceeded expectations, driven by strong revenues and margins.
The company's strategic strengths lie in customer wins, AI focus, and margin management.
Challenges include market dynamics and the need for ongoing adjustments.
Opportunities for growth include raised guidance, AI strategy development, and CMS impact.

Omnicell reports Q3 earnings, faces challenges but eyes growth opportunities

Omnicell's Q3 2023 performance reflects solid total revenues, EBITDA, and EPS, with market challenges impacting bookings and product lines. The company's strengths include customer wins, profitability, and strategic growth initiatives.
Challenges include revenue impact from reduced bookings, point-of-care revenue decline, and pipeline deal deferrals. Opportunities exist in Advanced Services growth, market expansion, and cost management strategies.
Omnicell's focus on profitability, revenue growth, and customer value delivery positions it for future success. The company's strategic actions and financial outlook indicate a proactive approach to addressing challenges and seizing opportunities.

Omnicell reports Q4 revenue decline but sees growth opportunities ahead

Omnicell's Q4 2023 performance saw revenue decline but highlighted strategic wins and a focus on operational optimization.
The company's strengths lie in customer engagement, product upgrades, and expansion into new markets.
Challenges include industry costs and regulatory hurdles, but opportunities exist in market growth and service enhancements.
Overall, Omnicell remains optimistic about future demand and revenue potential, with a conservative outlook for Q1.

Omnicell surpasses Q1 revenue targets, exits product line for value

Omnicell's Q1 2024 earnings call showcased strong performance exceeding guidance, with a focus on cost management and strategic initiatives. The company announced plans to exit an international product line to improve shareholder value. Opportunities lie in the growth of the XT Amplify program and EnlivenHealth brand, despite challenges in revenue decline and operational decisions.

Omnicell reports robust Q3 earnings, eyes growth in healthcare solutions

Omnicell's Q3 2024 performance reflects strong revenue growth and operational resilience in healthcare solutions.
The company's strategic focus on customer-centricity and innovation positions it for sustained success.
Challenges in product revenue timing and cost optimization require ongoing attention for operational efficiency.
Opportunities in expanding services and market positioning offer avenues for future growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Fort Worth, TX.

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Completes Acquisition of FDS Amplicare

Omnicell Completes Acquisition of FDS Amplicare

Omnicell (OMCL) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Is Omnicell (OMCL) a Solid Growth Stock? 3 Reasons to Think " Yes "

Computer Programs and Systems

Option Care Health

Here we discuss three major subsectors of MedTech and some of their constituent stocks for which COVID-19 has opened up enormous growth prospects.

3 MedTech Sectors Benefiting Despite COVID-19 Resurgence

Omnicell's (OMCL) new software development center in Bangalore, India, is expected to bolster the company's cloud-based solutions portfolio.

Omnicell (OMCL) Opens New Software Development Center in India

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced it has opened a new software development center via its India subsidiary based in Bangalore, India. Omnicell's new center will focus on product innovations to advance the Company's strategy to deliver the cloud-based infrastructure to support the Autonomous Pharmacy. The software development center in B

Omnicell Grows International Footprint with Opening of Omnicell India Software Development Center

IDEXX Laboratories

STAAR Surgical

Varex Imaging

Investors can choose to invest in MedTech stocks like VREX, OMCL, STAA, and IDXX that have shown tremendous promise amid the pandemic.

4 MedTechs to Gain in 2H21 Beating the Delta Variant-Led Dip

Omnicell's (OMCL) Summer 2021 Release offers greater platform deployment options, providing customers better flexibility and improving time to value for strategic initiatives.

Omnicell (OMCL) Enhances Medication Management With New Release

Omnicell (OMCL) possesses solid growth attributes, which could help it handily outperform the market.

Looking for a Growth Stock? 3 Reasons Why Omnicell (OMCL) is a Solid Choice

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced its latest enhancements to the Company's industry-leading portfolio of medication management solutions. The Summer 2021 Release is designed to deliver greater process efficiency, expand automation to support medication workflows, and provide greater intelligence for workflow optimization. The release al

Omnicell Announces Latest Advancements in Automation, Intelligence, and Technology-Enabled Services with Summer 2021 Release

Omnicell (OMCL) accelerates shift to cloud-based solutions and tech-enabled services through the launches of Omnicell One and Central Pharmacy Dispensing Services.

Omnicell (OMCL) Rides on New Buyout, Innovation Amid Pandemic

Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Omnicell (OMCL) Hits 52-Week High, Can the Run Continue?

Omnicell, Inc. (OMCL) CEO Randall Lipps on Q2 2021 Results - Earnings Call Transcript

Omnicell (OMCL) reports better-than-expected revenues on strong segmental performance driving the top line in second-quarter 2021.

Omnicell (OMCL) Q2 Earnings Top Estimates, 2021 EPS View Up

Omnicell Inc (NASDAQ: OMCL) reported second-quarter FY21 revenue growth of 36.6% year-on-year to $272.7 million, beating the analyst consensus of $268.5 million. The increase in revenues reflects momentum in commercial business and customer implementations and pandemic recovery.

Omnicell Beats On Q2 Earnings, Issues Promising Q3 Guidance

Omnicell (OMCL) delivered earnings and revenue surprises of 21.25% and 2.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Omnicell (OMCL) Tops Q2 Earnings and Revenue Estimates

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Spartanburg Regional Healthcare System Partners with Omnicell to Drive Improved Clinical and Operational Outcomes

Spartanburg Regional Healthcare System Partners with Omnicell to Drive Improved Clinical and Operational Outcomes

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its second quarter ended June 30, 2021. GAAP Results Total revenues for the second quarter of 2021 were $272.7 million, up $73.1 million, or 36.6%, from the second quarter of 2020. The increase in revenues reflects momentum in our commercial business and strong customer implementations a

Omnicell Announces Financial Results for Second Quarter 2021

Omnicell's (OMCL) second-quarter 2021 guidance includes additional freight costs, given the ongoing global market conditions.

Omnicell (OMCL) Faces Lingering Cost Woes, Fierce Competition

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Acquire FDS Amplicare

Omnicell to Acquire FDS Amplicare

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Appoints Edward Bousa to Board of Directors

Omnicell Appoints Edward Bousa to Board of Directors

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Release Second Quarter 2021 Financial Results on July 29, 2021

Omnicell to Release Second Quarter 2021 Financial Results on July 29, 2021

Omnicell (OMCL) and Chartwell partner to implement Omnicell's IVX Workflow for the management of chemotherapy drug product preparations.

Omnicell (OMCL)-Chartwell Partner to Implement IVX Workflow

PITTSBURGH--(BUSINESS WIRE)--Chartwell Enhances IV Preparations with Omnicell® IVX Workflow

Chartwell Enhances IV Preparations with Omnicell® IVX Workflow

Within the last quarter, Omnicell (NASDAQ:OMCL) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 1 1 0 Somewhat Bullish 1 0 1 0 Indifferent 0 1 0 0 Somewhat Bearish 0 0 0 0 Bearish 0 0 0 0 In the last 3 months, 5 analysts have offered 12-month price targets for Omnicell. The company has an average price target of $162.2 with a high of $188.00 and a low of $146.00.

Where Omnicell Stands With Analysts

Lordstown Motors

ResMed

Checkpoint Therapeutics

Helix Energy Solutions Group

Home Point Capital

Morgan Stanley

Renewable Energy Group

Weatherford International PLC

With the trading day about halfway over, the markets were trading sideways yet again, and it seems like the major averages may be stuck on this plateau.

News for Omnicell Stock (OMCL)